Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10665657rdf:typepubmed:Citationlld:pubmed
pubmed-article:10665657lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:10665657lifeskim:mentionsumls-concept:C0242643lld:lifeskim
pubmed-article:10665657lifeskim:mentionsumls-concept:C1704675lld:lifeskim
pubmed-article:10665657lifeskim:mentionsumls-concept:C0246415lld:lifeskim
pubmed-article:10665657lifeskim:mentionsumls-concept:C0699967lld:lifeskim
pubmed-article:10665657pubmed:issue12lld:pubmed
pubmed-article:10665657pubmed:dateCreated2000-2-28lld:pubmed
pubmed-article:10665657pubmed:abstractTextThe interaction of docetaxel ("Taxotere") with P-glycoprotein (P-gp) was examined using porcine kidney epithelial LLC-PK1 and LLC-GA5-COL150 cells, overexpressing human P-gp selectively on the apical plasma membrane by transfection of human MDR1 cDNA into the LLC-PK1 cells. The basal-to-apical transport of [14C]docetaxel in LLC-GA5-COL150 cells significantly exceeded that in LLC-PK1 cells, but the apical-to-basal transport was decreased in LLC-GA5-COL150 cells. The intracellular accumulation after its basal or apical application to LLC-GA5-COL150 cells was 4- to 20-fold lower than that of LLC-PK1 cells. Multidrug resistance (MDR) modulators, i.e., cyclosporin A and SDZ PSC 833, inhibited the basal-to-apical transport and increased the apical-to-basal transport of [14C]docetaxel in LLC-GA5-COL150 cells, but verapamil affected only apical-to-basal transport. The intracellular accumulation after basal or apical application to LLC-GA5-COL150 cells was also increased by these three MDR modulators. These observations demonstrated that docetaxel is a substrate for human P-gp, suggesting that docetaxel-drug interactions occur via P-gp. The inhibition of [14C]docetaxel transport by the MDR modulators, as well as daunorubicin and vinblastine, was also found in LLC-PK1 cells, which endogenously express P-gp at lower levels, and concentrations showing similar levels of inhibition were lower than those in the case of LLC-GA5-COL150 cells. These observations indicate that it is necessary to consider the pharmacokinetic and pharmacodynamic interactions of docetaxel via P-gp.lld:pubmed
pubmed-article:10665657pubmed:languageenglld:pubmed
pubmed-article:10665657pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10665657pubmed:citationSubsetIMlld:pubmed
pubmed-article:10665657pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10665657pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10665657pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10665657pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10665657pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10665657pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10665657pubmed:statusMEDLINElld:pubmed
pubmed-article:10665657pubmed:monthDeclld:pubmed
pubmed-article:10665657pubmed:issn0910-5050lld:pubmed
pubmed-article:10665657pubmed:authorpubmed-author:ShirakawaKKlld:pubmed
pubmed-article:10665657pubmed:authorpubmed-author:OkumuraKKlld:pubmed
pubmed-article:10665657pubmed:authorpubmed-author:AoyamaNNlld:pubmed
pubmed-article:10665657pubmed:authorpubmed-author:KasugaMMlld:pubmed
pubmed-article:10665657pubmed:authorpubmed-author:KomadaFFlld:pubmed
pubmed-article:10665657pubmed:authorpubmed-author:SakaedaTTlld:pubmed
pubmed-article:10665657pubmed:authorpubmed-author:TanigawaraYYlld:pubmed
pubmed-article:10665657pubmed:authorpubmed-author:TakaraKKlld:pubmed
pubmed-article:10665657pubmed:issnTypePrintlld:pubmed
pubmed-article:10665657pubmed:volume90lld:pubmed
pubmed-article:10665657pubmed:ownerNLMlld:pubmed
pubmed-article:10665657pubmed:authorsCompleteYlld:pubmed
pubmed-article:10665657pubmed:pagination1380-6lld:pubmed
pubmed-article:10665657pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10665657pubmed:meshHeadingpubmed-meshheading:10665657...lld:pubmed
pubmed-article:10665657pubmed:meshHeadingpubmed-meshheading:10665657...lld:pubmed
pubmed-article:10665657pubmed:meshHeadingpubmed-meshheading:10665657...lld:pubmed
pubmed-article:10665657pubmed:meshHeadingpubmed-meshheading:10665657...lld:pubmed
pubmed-article:10665657pubmed:meshHeadingpubmed-meshheading:10665657...lld:pubmed
pubmed-article:10665657pubmed:meshHeadingpubmed-meshheading:10665657...lld:pubmed
pubmed-article:10665657pubmed:meshHeadingpubmed-meshheading:10665657...lld:pubmed
pubmed-article:10665657pubmed:meshHeadingpubmed-meshheading:10665657...lld:pubmed
pubmed-article:10665657pubmed:meshHeadingpubmed-meshheading:10665657...lld:pubmed
pubmed-article:10665657pubmed:meshHeadingpubmed-meshheading:10665657...lld:pubmed
pubmed-article:10665657pubmed:meshHeadingpubmed-meshheading:10665657...lld:pubmed
pubmed-article:10665657pubmed:meshHeadingpubmed-meshheading:10665657...lld:pubmed
pubmed-article:10665657pubmed:meshHeadingpubmed-meshheading:10665657...lld:pubmed
pubmed-article:10665657pubmed:meshHeadingpubmed-meshheading:10665657...lld:pubmed
pubmed-article:10665657pubmed:year1999lld:pubmed
pubmed-article:10665657pubmed:articleTitleInteraction of docetaxel ("Taxotere") with human P-glycoprotein.lld:pubmed
pubmed-article:10665657pubmed:affiliationSecond Department of Internal Medicine, School of Medicine, Kobe University.lld:pubmed
pubmed-article:10665657pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10665657pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
literatureCitation:1588_106...literatureCitation:pubmedpubmed-article:10665657lld:drugbank
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10665657lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10665657lld:pubmed